Deals
Novartis Weighs Sale of Dermatology Generics Business
- Sale of dermatology assets could fetch up to $1.5 billion
- Assets may draw interest from buyout firms, strategic buyers
This article is for subscribers only.
Novartis AG is considering a sale of its dermatology generics drugs business as the Swiss health-care giant seeks to shed some of its less profitable treatments and focus on growth areas such as cancer, according to people familiar with the matter.
The business, which is mostly based in the U.S., could be valued at between $1 billion to $1.5 billion and attract both private equity firms and other drugmakers, the people said, asking not to be identified because the deliberations are private. The assets for sale include skin-care treatments and some manufacturing facilities, the people said.